SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Theragenics (TGX) on the up and up

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: glenn l holzer who wrote (930)7/3/1998 3:23:00 PM
From: K.Martin  Read Replies (2) of 1055
 
There are a couple of things that don't add up:
1. Why did Dain not downgrade all seed manufactures including NYE.URMD,etc.
2. One of Dain reasons was supply was being added quickly be NYE and that they therefore believe seeds will become a commodity. NYE is a large company and I do not believe that they would spend big bucks ramping up production if they believed first that their would be an oversupply of seeds on the market and second that the price of the seeds would go down a lot.
3. Unlike the SB report she did not seem to take into account any growth in the number of procedures done. THRX has approval to seel in Europe and is moving into Asia. The SB report seems much more well researched. The Dain report seems to be "off the cuff'.
This kind of reminds me of the canver scare a few years ago with respect to celluar phones where major manufactures went dond 20-30% overnight. I dont know what the stock of THRX will do short term but I still believe they will do well long term.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext